Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
Status:
Recruiting
Trial end date:
2026-09-12
Target enrollment:
Participant gender:
Summary
This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with
relapsed or refractory multiple myeloma, lymphoma, or solid tumors.